title: Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs.
authors.forename: Claudia
authors.initials: C
authors.lastname: Romano
authors.forename: Emanuele
authors.initials: E
authors.lastname: Sinagra
authors.forename: Valeria
authors.initials: V
authors.lastname: Criscuoli
authors.forename: Ambrogio
authors.initials: A
authors.lastname: Orlando
authors.forename: Simonetta
authors.initials: S
authors.lastname: Maisano
authors.forename: Mario
authors.initials: M
authors.lastname: Cottone
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D000069285:Infliximab; D008875:Middle Aged; D011014:Pneumonia / Q000453:epidemiology*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab